Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
申请人:——
公开号:US20020161022A1
公开(公告)日:2002-10-31
Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Novel proton type beta zeolite, preparation method thereof and process for preparing phenol compound using the same
申请人:UBE INDUSTRIES, LTD.
公开号:US20040242938A1
公开(公告)日:2004-12-02
Disclosed are a proton type &bgr; zeolite in which an acid site showing a desorption peak with a range of ±100° C. with a center of 330° C. exists in a spectrum measured by the ammonia temperature programmed desorption method (NH
3
-TPD), and an amount of a strong acid site showing a desorption peak of 500° C. or higher is controlled to 2.5 &mgr;mol/g or less, a method for preparing the same, and a process for preparing a phenol compound by oxidizing a benzene compound with a peroxide in the presence of the proton type &bgr; zeolite.
Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)
Nouvelle Zéolite Beta de type protonique, son procédé de préparation et procédé de préparation de composés phénoliques la mettant en oeuvre
申请人:Ube Industries, Ltd.
公开号:EP1481730A1
公开(公告)日:2004-12-01
L'invention est relative à une zéolite β de type protonique comportant un site acide présentant un pic de désorption dans une gamme de ± 100°C avec un centre à 330°C, selon un spectre mesuré par la méthode de désorption à l'ammoniaque à température programmée (TPD-NH3), et une quantité de site acide fort présentant un pic de désorption à une température d'au moins 500°C inférieure ou égale à 2,5 µmole/g, à son procédé de préparation, ainsi qu'à un procédé de préparation d'un composé phénolique consistant à oxyder un composé benzénique avec un peroxyde en présence de ladite zéolite β de type protonique.